Abstract: A propulsion system having an electric motor and corresponding method. A controller is configured to receive a torque request and selectively command the electric motor. The controller has a processor and tangible, non-transitory memory on which instructions are recorded for a method of generating an auxiliary power. The controller is configured to obtain a desired auxiliary power and a delta factor (?). The delta factor is set as a speed modifier (??=?) when the cosine of an angle (?), between a constant torque unit vector and a decreasing voltage ellipse unit vector, is less than a predefined threshold. A modified rotor speed is obtained as a sum of an original rotor speed and a speed modifier (??). The controller is configured to obtain modified stator current commands based on the modified rotor speed and torque request. The auxiliary power is generated by commanding the modified stator current commands.

Abstract: A system and method for controlling an exercise device are provided herein. The system includes a memory having computer-executable instructions and at least one processor to execute the computer-executable instructions to wirelessly connect the exercise device, receive a training mode, receive at least one variable for determining a power set point, determine the power set point responsive to the training mode and the at least one variable and control a magnetic brake assembly in the exercise device responsive to the power set point.

Abstract: Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology.